26 July 2013 | News | By BioSpectrum Bureau
Phylogica is collaborating with Cubist Pharmaceuticals in order to evaluate several of its antimicrobial Phylomers
Singapore: Phylogica is collaborating with Cubist Pharmaceuticals in order to evaluate several of its antimicrobial Phylomers in models of multi-drug resistant bacterial infections.
Dr Paul Watt, CSO, Phylogica, said that, "I am delighted to have the opportunity to collaborate with one of the world's leading developers of antimicrobial drugs. Through this collaboration, we hope that Phylogica's antimicrobial Phylomers will support Cubist's ongoing work to discover and develop new antibiotics to address the growing global health threat of antibiotic resistance."
He added, "In Phylogica's own assays, these antimicrobials have shown activity against multi-resistant isolates of Gramnegative organisms, which are a major cause of deaths from hospital acquired infections of burn wounds".